Cambium Bio Ltd (CMB) - Total Assets
Based on the latest financial reports, Cambium Bio Ltd (CMB) holds total assets worth AU$3.30 Million AUD (≈ $2.33 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cambium Bio Ltd (CMB) net assets for net asset value and shareholders' equity analysis.
Cambium Bio Ltd - Total Assets Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd's total assets have evolved over time, based on quarterly financial data.
Cambium Bio Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Cambium Bio Ltd's total assets of AU$3.30 Million consist of 14.2% current assets and 85.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 5.1% |
| Accounts Receivable | AU$275.72K | 8.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$2.45 Million | 74.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cambium Bio Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cambium Bio Ltd's current assets represent 14.2% of total assets in 2025, a decrease from 21.0% in 1999.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2025, down from 15.1% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is intangible assets at 74.3% of total assets.
Cambium Bio Ltd Competitors by Total Assets
Key competitors of Cambium Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Cambium Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.36 | 1.33 | 0.96 |
| Quick Ratio | 0.36 | 1.33 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-825.44K | AU$795.18K | AU$-148.22K |
Cambium Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Cambium Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.13 |
| Latest Market Cap to Assets Ratio | 2.02 |
| Asset Growth Rate (YoY) | -41.7% |
| Total Assets | AU$3.30 Million |
| Market Capitalization | $6.66 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cambium Bio Ltd's assets at a significant premium (2.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cambium Bio Ltd's assets decreased by 41.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cambium Bio Ltd (1999–2025)
The table below shows the annual total assets of Cambium Bio Ltd from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$3.30 Million ≈ $2.33 Million |
-41.67% |
| 2024-06-30 | AU$5.65 Million ≈ $4.00 Million |
+127.41% |
| 2023-06-30 | AU$2.48 Million ≈ $1.76 Million |
-2.76% |
| 2022-06-30 | AU$2.55 Million ≈ $1.81 Million |
-69.98% |
| 2021-06-30 | AU$8.51 Million ≈ $6.02 Million |
+77.69% |
| 2020-06-30 | AU$4.79 Million ≈ $3.39 Million |
+88.43% |
| 2019-06-30 | AU$2.54 Million ≈ $1.80 Million |
-48.99% |
| 2018-06-30 | AU$4.98 Million ≈ $3.53 Million |
-45.63% |
| 2017-06-30 | AU$9.16 Million ≈ $6.48 Million |
+54.42% |
| 2016-06-30 | AU$5.93 Million ≈ $4.20 Million |
-38.05% |
| 2015-06-30 | AU$9.58 Million ≈ $6.78 Million |
-6.63% |
| 2014-06-30 | AU$10.26 Million ≈ $7.26 Million |
+154.98% |
| 2013-06-30 | AU$4.02 Million ≈ $2.85 Million |
+22.06% |
| 2012-06-30 | AU$3.30 Million ≈ $2.33 Million |
-21.71% |
| 2011-06-30 | AU$4.21 Million ≈ $2.98 Million |
+131.22% |
| 2010-06-30 | AU$1.82 Million ≈ $1.29 Million |
-96.37% |
| 2002-06-30 | AU$50.20 Million ≈ $35.52 Million |
-84.57% |
| 2001-06-30 | AU$325.41 Million ≈ $230.25 Million |
+12.46% |
| 2000-06-30 | AU$289.37 Million ≈ $204.74 Million |
+2.82% |
| 1999-06-30 | AU$281.42 Million ≈ $199.12 Million |
-- |
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more